Charles River Laboratories International (NYSE:CRL) Stock: Insider Shannon Parisotto Sells 981 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 981 shares of the business’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $308.44, for a total transaction of $302,579.64. Following the completion of the sale, the executive vice president owned 4,807 shares in the company, valued at $1,482,671.08. This represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

CRL stock traded down $4.75 on Wednesday, reaching $300.21. The company had a trading volume of 1,242,167 shares, compared to its average volume of 1,048,482. The company’s fifty day moving average is $281.78 and its 200 day moving average is $221.18. The company has a market cap of $14.33 billion, a P/E ratio of -61.90, a PEG ratio of 2.86 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $333.30.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period in the previous year, the firm posted $3.12 earnings per share. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 11.36 earnings per share for the current year.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analysts raised earnings forecasts. Zacks Research increased its FY2026 EPS estimate to $11.17 from $11.15, FY2027 to $12.54 from $12.49, and FY2028 to $13.92 from $13.82. It also made modest upward revisions to several quarterly estimates and maintained a “Strong-Buy” rating. Zacks Research earnings forecast
• Positive Sentiment: UBS upgraded CRL to Strong Buy, providing additional institutional support after the company’s substantial 12-month advance. UBS upgrade
• Positive Sentiment: Operational momentum remains a key bullish theme. Recent coverage points to improving Research Models and Services trends, expanding AI-enabled testing, healthy cash flow, and the ability to fund share buybacks and investment. Charles River rally analysis
• Positive Sentiment: Charles River and Autolomous launched Apollo Orchestrate, a digital laboratory-execution solution integrated within Charles River’s Apollo platform. The initiative could strengthen the company’s technology offering and improve laboratory efficiency. Apollo Orchestrate launch
• Neutral Sentiment: A Zacks comparison examines whether CRL or Progyny offers the more attractive value opportunity. The article may influence valuation-focused investors, but the headline does not disclose a definitive preference. PGNY versus CRL value analysis
• Negative Sentiment: Valuation and recent gains may be limiting near-term upside. With CRL near its 12-month high after a powerful rally, investors may be taking profits while awaiting further earnings confirmation. The company’s latest reported revenue declined 2.7% year over year, adding a reason for caution despite earnings beating estimates.

Analysts Set New Price Targets

CRL has been the topic of several analyst reports. CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a report on Monday, July 20th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Royal Bank Of Canada upped their price target on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Barclays raised their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an “overweight” rating in a report on Friday, September 25th. Finally, Evercore set a $330.00 price objective on Charles River Laboratories International in a report on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $300.11.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Empirical Finance LLC lifted its position in Charles River Laboratories International by 4.4% in the 2nd quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock valued at $333,000 after purchasing an additional 62 shares during the last quarter. Glenmede Trust Co. NA increased its stake in shares of Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after purchasing an additional 73 shares during the period. Syon Capital LLC increased its stake in shares of Charles River Laboratories International by 2.4% in the second quarter. Syon Capital LLC now owns 3,547 shares of the medical research company’s stock valued at $804,000 after purchasing an additional 83 shares during the period. Brown Miller Wealth Management LLC raised its holdings in shares of Charles River Laboratories International by 7.0% during the first quarter. Brown Miller Wealth Management LLC now owns 1,278 shares of the medical research company’s stock valued at $220,000 after buying an additional 84 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Charles River Laboratories International by 0.6% during the second quarter. Arizona State Retirement System now owns 13,615 shares of the medical research company’s stock valued at $3,088,000 after buying an additional 86 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.